- Home
- WRBY vs NVCR Comparison
WRBY vs NVCR Comparison
Compare WRBY & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WRBY
- NVCR
- Stock Information
- Founded
- WRBY 2010
- NVCR 2000
- Country
- WRBY United States
- NVCR Switzerland
- Employees
- WRBY N/A
- NVCR N/A
- Industry
- WRBY Ophthalmic Goods
- NVCR Medical/Dental Instruments
- Sector
- WRBY Health Care
- NVCR Health Care
- Exchange
- WRBY Nasdaq
- NVCR Nasdaq
- Market Cap
- WRBY 2.1B
- NVCR 1.9B
- IPO Year
- WRBY 2021
- NVCR 2015
- Fundamental
- Price
- WRBY $22.24
- NVCR $17.71
- Analyst Decision
- WRBY Buy
- NVCR Buy
- Analyst Count
- WRBY 15
- NVCR 6
- Target Price
- WRBY $23.33
- NVCR $32.83
- AVG Volume (30 Days)
- WRBY 1.9M
- NVCR 1.6M
- Earning Date
- WRBY 08-07-2025
- NVCR 07-24-2025
- Dividend Yield
- WRBY N/A
- NVCR N/A
- EPS Growth
- WRBY N/A
- NVCR N/A
- EPS
- WRBY N/A
- NVCR N/A
- Revenue
- WRBY $795,094,000.00
- NVCR $621,711,000.00
- Revenue This Year
- WRBY $16.13
- NVCR $5.56
- Revenue Next Year
- WRBY $13.87
- NVCR $9.19
- P/E Ratio
- WRBY N/A
- NVCR N/A
- Revenue Growth
- WRBY 13.94
- NVCR 18.27
- 52 Week Low
- WRBY $12.46
- NVCR $14.17
- 52 Week High
- WRBY $28.68
- NVCR $34.13
- Technical
- Relative Strength Index (RSI)
- WRBY 60.97
- NVCR 51.32
- Support Level
- WRBY $21.48
- NVCR $17.53
- Resistance Level
- WRBY $22.52
- NVCR $18.70
- Average True Range (ATR)
- WRBY 0.76
- NVCR 0.72
- MACD
- WRBY -0.13
- NVCR 0.09
- Stochastic Oscillator
- WRBY 83.48
- NVCR 60.56
About WRBY Warby Parker Inc.
Warby Parker Inc is a mission-driven, lifestyle brand that operates at the intersection of design, technology, healthcare, and social enterprise. The company predominantly derives revenue from the sales of eyewear products, optical services, and accessories. The firm sells products and services through its stores, website, and mobile apps. Revenue generated from eyewear products includes the sales of prescription and non-prescription optical glasses and sunglasses, contact lenses, eyewear accessories, and expedited shipping charges.
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.